Swiss biotech startup closes the Series A round at CHF 5,05 million
scroll south
Congratulations to Venturelab alumnus Glycemicon, who have announced the final closing of the Series A round.
After announcing the initial funding of CHF 3,25 million in January 2017, the TOP 100 and Venture Kick alumnus, has officially closed the Series A round with an additional CHF 1,8 million, which brings the total funding to CHF 5,05 million.About Glycemicon
Glycemicon AG is a Swiss biotechnology company developing novel nutraceuticals for managing prediabetes, diabetes and obesity, using new approaches that were initially developed at the University of Science & Technology ETH Zurich. The lead product’s active substance is a natural occurring tetrahydroxylated bile acid (THBA) in both humans and pets, which drives the formation of new fat cells to combat elevated blood glucose levels. The resulting greater number of smaller fat cells does not result in weight gain, but significantly improves the effectiveness of nutrient storage, increases insulin sensitivity and enables better control of blood sugar levels.